This HND piece puts the spotlight on an interesting approach to developing a COVID-19 vaccine: DNA medicine. The idea here is that DNA plasmids are introduced via a special device into the cell. There they trigger T cells to do their thing against the invading COVID virus. The company behind this unique approach is Inovio Pharmaceuticals.
Inovio has had some real success with MERS, caused by a related coronavirus, and initial studies look good for COVID. At present, Inovio is having some issues with one of its sub-contractors, and that is the subject of litigation, which hopefully should be resolved soon.
Read the complete article.